Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prognostic Stage IV Breast Cancer AJCC v8: early-phase trial registry
4 of 10 indexed Prognostic Stage IV Breast Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Prognostic Stage IV Breast Cancer AJCC v8: 10 US clinical trials tracked, 4 recruiting.
Prognostic Stage IV Breast Cancer AJCC v8 is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Roswell Park Cancer Institute, running 2 of these trials.
Enrollment posture brief
Registry condition prognostic-stage-iv-breast-cancer-ajcc-v8
OPEN 4 | RECR 40% | LATE 0 | EARLY 7 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)
Prognostic Stage IV Breast Cancer AJCC v8 lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prognostic Stage IV Breast Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prognostic Stage IV Breast Cancer AJCC v8 is recruiting below its size-band peers.
4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Prognostic Stage IV Breast Cancer AJCC v8 research.
Roswell Park Cancer Institute accounts for 2 of 10 trials (20%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Prognostic Stage IV Breast Cancer AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 44 among the 10 trials that report a genuine target (sentinel values excluded). 6 of those (60%) plan for fewer than 100 participants.
-
Prognostic Stage IV Breast Cancer AJCC v8 research is mostly interventional.
9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
SWOG Cancer Research Network
NCT03723928
Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors
Roswell Park Cancer Institute
NCT04526587
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
City of Hope Medical Center
NCT04305834
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Roswell Park Cancer Institute
NCT04348747
A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer
Ohio State University Comprehensive Cancer Center
NCT05215769
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
ECOG-ACRIN Cancer Research Group
NCT04316117
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
SWOG Cancer Research Network
NCT04647916
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
Mridula George, MD
NCT04445844
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
NCT04616248
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
NCT05081492
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Prognostic Stage IV Breast Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prognostic Stage IV Breast Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prognostic Stage IV Breast Cancer AJCC v8 page
10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Prognostic Stage IV Breast Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Roswell Park Cancer Institute sponsors the most Prognostic Stage IV Breast Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See Roswell Park Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prognostic Stage IV Breast Cancer AJCC v8 condition card totals 10 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.